Gerrit Jan Wolbink

Summary

Country: The Netherlands

Publications

  1. ncbi Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
    Gerrit Jan Wolbink
    Department of Immunopathology, CLB Sanquin Amsterdam and Jan van Breeman Institute, Amsterdam, The Netherlands
    Arthritis Rheum 54:711-5. 2006
  2. doi Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 72:1680-6. 2013
  3. doi The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
    Anna Jamnitski
    Jan van Breemen Institute, Amsterdam, The Netherlands
    Ann Rheum Dis 70:284-8. 2011
  4. doi Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
    Geertje M Bartelds
    Jan van Breemen Research Institute, Amsterdam, The Netherlands
    JAMA 305:1460-8. 2011
  5. ncbi Drug interference in immunogenicity assays depends on valency
    Theo Rispens
    Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, The Netherlands
    J Pharm Biomed Anal 85:179-85. 2013
  6. doi Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 72:104-9. 2013
  7. doi IgG4 production against adalimumab during long term treatment of RA patients
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
    J Clin Immunol 32:1000-6. 2012
  8. doi The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia
    Lotte A van de Stadt
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratorium, Academic Medical Center, Amsterdam, The Netherlands
    Ann Rheum Dis 70:128-33. 2011
  9. doi Differential effect of drug interference in immunogenicity assays
    Margreet H Hart
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory AMC, Amsterdam, The Netherlands
    J Immunol Methods 372:196-203. 2011
  10. doi A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
    J Immunol Methods 362:82-8. 2010

Collaborators

Detail Information

Publications14

  1. ncbi Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
    Gerrit Jan Wolbink
    Department of Immunopathology, CLB Sanquin Amsterdam and Jan van Breeman Institute, Amsterdam, The Netherlands
    Arthritis Rheum 54:711-5. 2006
    ..This study evaluated the clinical significance of these antibodies in patients with rheumatoid arthritis (RA)...
  2. doi Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 72:1680-6. 2013
    ..Measurement of ADA in the presence of (high) drug levels is difficult due to drug interference in most assays, including the commonly used antigen binding test (ABT)...
  3. doi The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
    Anna Jamnitski
    Jan van Breemen Institute, Amsterdam, The Netherlands
    Ann Rheum Dis 70:284-8. 2011
    ..The aim of this study was to test the hypothesis that the reason for non-response (caused by immunogenicity or not) to a first tumour necrosis factor (TNF) inhibitor defines whether a second TNF inhibitor will be effective...
  4. doi Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
    Geertje M Bartelds
    Jan van Breemen Research Institute, Amsterdam, The Netherlands
    JAMA 305:1460-8. 2011
    ..Little is known about the clinical relevance of antidrug antibodies against these drugs during long-term follow-up...
  5. ncbi Drug interference in immunogenicity assays depends on valency
    Theo Rispens
    Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, The Netherlands
    J Pharm Biomed Anal 85:179-85. 2013
    ..When comparing immunogenicity data obtained for different biologicals this phenomenon should be taken into account. ..
  6. doi Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, Amsterdam, The Netherlands
    Ann Rheum Dis 72:104-9. 2013
    ..A study was undertaken to determine the mechanism by which AAA lead to loss of response...
  7. doi IgG4 production against adalimumab during long term treatment of RA patients
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
    J Clin Immunol 32:1000-6. 2012
    ..Here, we investigate whether long term treatment of RA patients with the therapeutic monoclonal antibody adalimumab leads to the production of specific IgG4 antibodies...
  8. doi The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia
    Lotte A van de Stadt
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratorium, Academic Medical Center, Amsterdam, The Netherlands
    Ann Rheum Dis 70:128-33. 2011
    ..To determine the fine specificity of anti-citrullinated protein antibodies (ACPA) in the early phase of arthritis development, the ACPA repertoire in arthralgia patients and the association with arthritis development were studied...
  9. doi Differential effect of drug interference in immunogenicity assays
    Margreet H Hart
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory AMC, Amsterdam, The Netherlands
    J Immunol Methods 372:196-203. 2011
    ..In summary, we showed that a bridging elisa is susceptible to drug interference and typically measures ADA only in absence of detectable drug levels...
  10. doi A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
    J Immunol Methods 362:82-8. 2010
    ..It revealed ADA in 21 out of 30 tested patients, while the ABT detected ADA in only 5 patients. Indicating that an immunogenic reaction towards adalimumab is present in the majority of adalimumab treated patients...
  11. doi Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
    Pauline A van Schouwenburg
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands
    Nat Rev Rheumatol 9:164-72. 2013
    ....
  12. ncbi Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis
    Wouter H Bos
    Jan van Breemen Instituut, Sanquin Research, and VU University Medical Center, Department of Rheumatology, Amsterdam, The Netherlands
    J Rheumatol 35:1972-7. 2008
    ..To investigate the effect of anti-tumor necrosis factor (TNF) treatment on rheumatoid factor (IgM-RF) and anticitrullinated protein antibodies (ACPA) and its association with treatment response and acute-phase reactants...
  13. pmc Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation
    Mirjam K de Vries
    VU University Medical Centre, Rheumatology Department, room 4A 42, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 66:1252-4. 2007
    ..Correlation of serum trough infliximab levels and antibodies to infliximab (anti-infliximab) with clinical response in ankylosing spondylitis...
  14. pmc Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
    Geertje M Bartelds
    Jan van Breemen Institute, 1056 AB Amsterdam, The Netherlands
    Ann Rheum Dis 66:921-6. 2007
    ..A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that patients develop anti-adalimumab antibodies...